- €445.36m
- €510.81m
- €65.43m
Brief: Genfit To Present New Clinical Data On Investigational Compound Elafibranor
Brief: Genfit Reports First Half-Year 2021 Financial Results And Provides Corporate Update
Brief: Genfit Q1 Cash Position EUR 108.9 Mln
Brief: Genfit: Cash, Cash Equivalents Of EUR 109 Mln At End-March
Brief: Genfit Announces Launch By Labcorp Of NASHnext
Genfit: Launch of NASHnext liver disease test lifts shares
Brief: Genfit Hires Thomas Baetz As CFO, Adds New ExCo Members
French and Benelux stocks-Factors to watch
Brief: Genfit 2020 Revenues Down At 765,000 Euros
Genfit: Positive liver disease drug results boost shares
Genfit: Shares soar on convertible bonds buyback
Brief: Genfit: Approval Of OCEANEs Buyback And Amendments Of Terms
Advisory: Alert on Genfit SA from law firm withdrawn
Brief: Genfit Renegotiates OCEANEs Convertible Bond Terms
Brief: Euronext Announces Quarterly Revision Of CAC Family Indices
Brief: Genfit Hits Milestone In Partial Buyback, OCEANEs Amendment
Brief: Genfit Announces Final Terms For Proposed Renegotiation Of 2022 OCEANE Convertible Bonds
Brief: Genfit 9M Revenue Down To 350,000 Euros
U.S. STOCKS ON THE MOVE-Eli Lilly, Twitter, Harley-Davidson, Chegg Inc